Hospital where JFK died struggles to be redeveloped

Parkland Hospital in Dallas saw its most famous patient on Nov. 22, 1963, when President John F. Kennedy was rushed into its emergency room and pronounced dead from gunshot wounds. Now, that same hospital campus is on the market, but it can’t seem to get past development problems.

Less than a month ago, a developer had been given the OK to buy the 38-acre campus to convert the old buildings into housing, offices and retail space. A key deadline to secure financing for the transaction has been missed, and now Parkland is putting the campus back up for sale.

"Parkland has been notified that Dreien Opportunities LLC, who had entered into an $83.3 million deal to purchase the former Parkland Memorial Hospital campus, was not able to complete and close the necessary financing within the time frame required under the purchase agreement," Parkland senior vice president Michael Malaise said in a statement to the Dallas Morning News.

Parkland is still serving Dallas residents just across the street in a $1.3 billion hospital which opened in 2016. The old Parkland has sat vacant ever since.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.